Edwards Lifesciences (EW) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Edwards Lifesciences (EW) overview

Edwards Lifesciences (EW) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 6,068m and operating profit of USD 1,264m; the year-end share price was 85.25 USD and market capitalisation was USD 49,505m. Edwards Lifesciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Edwards Lifesciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 10,338mFY 2025
Share price85.25 USDFY 2025 year end
RevenueUSD 6,068mFY 2025
Operating profitUSD 1,264mFY 2025
Net earningsUSD 1,074mFY 2025
Market capitalisationUSD 49,505mFY 2025 year end

About Edwards Lifesciences

Edwards Lifesciences develops medical technologies for structural heart disease, including surgical and transcatheter therapies. Its products include repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves, such as bioprosthetic surgical valves, annuloplasty rings, transcatheter valves and repair systems. These products are used by cardiac surgeons and interventional cardiologists to treat patients with heart valve disorders.

Generate the Edwards Lifesciences report

Edwards Lifesciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Edwards Lifesciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Edwards Lifesciences

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.